The Pragmatica-Lung study (NCT05633602), investigating the combination of ramucirumab and pembrolizumab for the treatment of Stage IV or recurrent non-small cell lung cancer (NSCLC), is scheduled to reach primary completion on 2025-11-26. This Phase 3 trial compares the investigational regimen against standard of care chemotherapy.
Background
Pembrolizumab (Keytruda) is an immunotherapy that helps the body's immune system attack cancer cells. Ramucirumab is a monoclonal antibody designed to prevent the growth of new blood vessels that tumors need to grow. This study focuses on patients with Stage IV or recurrent non-small cell lung cancer who have previously received immunotherapy.
Trial design
The Pragmatica-Lung study (NCT05633602) is a Phase 3 trial with an estimated enrollment of 838 participants. The study is evaluating treatment for patients with Recurrent Lung Non-Small Cell Carcinoma and Stage IV Lung Cancer AJCC v8. Interventions include chemotherapy, pembrolizumab, and ramucirumab. The trial compares the combination of ramucirumab plus pembrolizumab against usual care chemotherapy.
What this means
The scheduled primary completion of the Pragmatica-Lung study signifies that data collection for the trial's primary endpoint is expected to conclude by November 2025. This milestone is a critical step before the data can be analyzed and results reported, which will inform the potential role of ramucirumab plus pembrolizumab in treating advanced NSCLC following prior immunotherapy. Clinicians and researchers will await these results to understand the efficacy and safety profile of this combination compared to current standard treatments.
Source
Information regarding the primary completion schedule for the Pragmatica-Lung study (NCT05633602) was obtained from ClinicalTrials.gov, a public database of clinical studies. The update was noted with an event date of 2025-11-26 on clinicaltrials.gov.